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Nearly 300 experts in tuberculosis (TB) and TB vaccine research
and development (R&D) from more than 30 countries around the
world gathered in Shanghai from April 21e24, 2015, for the 4th
Global Forum on TB Vaccines (the 4th Global Forum). The biannual
Global Forum on TB Vaccines is convened by and for the TB vaccine
research community under the auspices of the Stop TB Partnership
Working Group on New Vaccines.
The 4th Global Forum provided updates on the latest efforts in TB
vaccine R&D, including new and innovative approaches. More than
65 speakers in 17 sessions and 51 posters presented on a full range of
topics, including the progress of clinical candidates; research related
to epidemiology, biomarkers and correlates; new approaches to an-
imal models; and novel clinical trial designs and strategies. Re-
searchers also discussed strategies to diversify the global pipeline
of TB vaccines under development, as well as the importance of in-
ternational collaboration in both research and advocacy.
Hosting the 4th Global Forum in Shanghai e the ﬁrst time this
important event was held in Asia – provided a unique opportunity
for participants to gain insights into TB vaccine R&D in China.
Several TB experts in China participated in the Opening Session.
Dr. Lixia Wang (National Center for Tuberculosis Control and Pre-
vention, Chinese Center for Disease Control and Prevention) Dr.
Ping Chen (NIAID Ofﬁce in China), Dr. Lixing Zhang (Beijing
Research Institute for Tuberculosis), and Dr. Wenjun Sun (Bill &
Melinda Gates Foundation, China Ofﬁce) spoke about the country's
TB burden and its commitment to improving diagnosis and treat-
ment, as well as R&D for new tools, including vaccines; and Dr.
Mario Raviglione (WHO Global TB Programme) and Dr. Fabio Scano
(WHO Beijing) provided welcoming remarks from the World
Health Organization. Some of China's leading researchers pre-
sented their work throughout the Forum, in areas such as
biomarker identiﬁcation, clinical research, epidemiology, antigen
discovery and immunopathogenesis of TB. There was a large dele-
gation from China in attendance, including a number of students
and early career researchers, providing an opportunity for
networking and the potential to identify new partners and collab-
orators. Four Chinese institutions e Shanghai Institute of Biological
Products, Shanghai Pulmonary Hospital, Shanghai Public Health
Clinical Center, and The Center for Animal Experiment at Wuhan
University e hosted site visits for participants, giving them a ﬁrst-
hand view of TB research and care in China.
TB vaccine R&D is an evolving ﬁeld, as new ﬁndings inform
research and new approaches are identiﬁed and explored. TBhttp://dx.doi.org/10.1016/j.tube.2016.05.009
1472-9792/© 2016 Published by Elsevier Ltd. This is an open access article under the CCvaccine R&D also requires partnership and collaboration in order
to accelerate and advance the ﬁeld in an efﬁcient and cost-
effective manner. The biannual Global Forum on TB Vaccines is
the only convening that provides the opportunity for stakeholders
from all areas of TB vaccine R&D – from early stage research, to clin-
ical trials, manufacturing and licensure, to advocacy – to come
together to understand how research is evolving, to discuss and
prepare for the future, and to foster and promote partnerships.
This special supplement provides an overview of the sessions
and discussion that took place during the 4th Global Forum on TB
Vaccines. Where permission has been granted, presentations
from the 4th Global Forum on TB Vaccines will be available on
the Forum website (www.tbvaccines2015.org) through 2017.
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